骨髓增殖性肿瘤患者静脉血栓栓塞抗栓治疗的系统综述
随访中23%发生动脉或复发性静脉血栓事件,口服抗凝联合降细胞治疗者复发风险最低(16%),证据确定性低。
要点
- MPN合并VTE史患者随访血栓事件复发率23%,抗凝联合降细胞治疗复发风险最低。
- 维生素K拮抗剂联合降细胞治疗复发18%,直接口服抗凝药联合降细胞治疗复发8%。
- 所有抗栓治疗联合降细胞治疗均与降低复发性VTE风险相关,但证据仅来自观察性研究。
核心结论
- MPN合并VTE史患者的最佳长期抗栓治疗证据仅基于观察性研究,所有策略证据确定性低。
- 抗凝联合降细胞治疗可能提供最低的复发风险。
研究设计与样本
- 系统综述与荟萃分析,筛选5675条唯一文献,未识别到随机对照试验。
主要发现
- 随访中23%患者发生动脉或复发性静脉血栓事件。
- 口服抗凝联合降细胞治疗者复发风险最低(16%);维生素K拮抗剂(VKA)治疗者55/313(18%)复发,直接口服抗凝药(DOAC)治疗者5/63(8%)复发。
- 746例分析患者中复发性VTE风险最高达33%(中位13%),63例DOAC联合降细胞治疗者复发风险低(3.2%)。
- 所有类型抗栓治疗联合降细胞治疗均与降低复发性VTE风险相关。
关键数值与推荐
- 复发性VTE风险:整体最高33%,中位13%。
- 口服抗凝联合降细胞治疗复发风险16%;VKA治疗18%(55/313);DOAC治疗8%(5/63);DOAC联合降细胞治疗3.2%(63例中)。
临床怎么用
- 对有VTE史的MPN患者,可考虑抗凝联合降细胞治疗以降低复发风险。
- 临床决策需结合个体情况,因证据确定性低且研究异质性大。
局限性
- 无随机对照试验,仅纳入观察性研究。
- 多数研究存在高偏倚风险。
- 临床和统计异质性导致结果不一致且不精确。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Patients with myeloproliferative neoplasms (MPNs), polycythemia vera, essential thrombocythemia, and primary myelofibrosis, have an increased risk of thrombosis. Risk of recurrent thrombosis can be reduced with antithrombotic therapy and/or cytoreduction, but the optimal long-term management in patients with MPN with a history of venous thromboembolism (VTE) is unknown, and clinical practice is heterogeneous. We performed a systematic review and meta-analysis of randomized trials and observational studies evaluating anticoagulant and/or antiplatelet therapy, with or without cytoreduction, in MPN patients with a history of VTE. A total of 5675 unique citations were screened for eligibility. No randomized trials were identified. Ten observational studies involving 1295 patients with MPN were included in the analysis. Overall, 23% had an arterial or recurrent venous thrombotic event on follow-up. The recurrence risk was lowest for patients on oral anticoagulation plus cytoreduction (16%); 55 of 313 (18%) with vitamin K antagonists (VKA) and 5 of 63 (8%) with direct oral anticoagulants (DOACs). In 746 analyzed patients, the risk of recurrent VTE ranged up to 33% (median 13%) and was low in 63 DOAC plus cytoreduction-treated patients (3.2%). All types of antithrombotic treatments were associated with a lower risk of recurrent VTE when combined with cytoreduction. Most studies had a high risk of bias, whereas clinical and statistical heterogeneity led to inconsistent and imprecise findings. In summary, evidence on the optimal antithrombotic treatment of VTE in patients with MPN is based on observational studies only with low certainty for all strategies. Our data suggest that a combination of anticoagulation and cytoreduction may provide the lowest recurrence risk.
引用
- Hamulyák EN, Daams JG, Leebeek FWG, et al. A systematic review of antithrombotic treatment of venous thromboembolism in patients with myeloproliferative neoplasms. Blood Adv. 2021. PMID: 33570633. doi:10.1182/bloodadvances.2020003628
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。